Technology & Services
Technology & Services
Biologics Production in Global Demand
Biologics are one key growth driver in pharmaceutical and biotechnology industries. The global biologics market was valued at US$ 251.5 billion in 2018, US$ 255.19 billion in 2019, and is projected to surpass US$ 456.8 billion by 2027. A booming necessity for biologics in the drug market is driving the global demand for biologics manufacturing capacity.
Antagen Technology Platforms: Antibody Expression System
AntagenPharma has pioneered the biologics production through its innovative fast-track and high-efficiency antibody expression system. The expression system not only shortens the development time of stable CHO cell lines to 4-5 months from traditional 9-12 months, but also significantly increases the expression yields of target antibodies.
Antagen Genetic Elements
Scientists at AntagenPharma has developed proprietary Antagen Genetic Elements (AGE) that were discovered with a novel bioinformatics tool and are now utilized to control the dynamic organization of trans-genes in the chromatin.
Key Advantages
- Fast and Highly-Stringent Screening: Only high-productivity stable CHO cell clones are obtained in 4-5 months
- High targeting efficiency: Reduce the workload of screening and subcloning for establishing cell lines
- High Yield: Antibody expression levels at rates typically ranging from 30 to 70 p/c/d/
- High Stability: Antagen Genetic Elements prevents the epigenetic silencing effect; integration into a ‘hot spot’ further safeguards the cell line stability
- Screening with GS: Glutamine synthetase (GS) gene on the plasmid can be used as an alternative screening marker to get stable CHO cell clones with further increase in antibody production yield.
AntagenPharma has developed proprietary CHO cell lines with altered (enhanced or eliminated) expression of glycosylation enzymes for fucosylation, sialylation and galactosylation. These top-notch tools allow us to express well-defined, uniform antibody glyco-types, which confers the desired biological properties for the target application. This approach offers significant benefits, such as enhanced Fc effector functions, improved safety profiles, higher batch-to-batch consistency, decreased risks related to immunogenicity and manufacturing process changes, and the possibility to manufacture antibodies, in an economical manner.